Clinical Trial Update: To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial to assess the effect of a single oral dose of MY008211A on QTc interval in healthy subjects; the study is not yet recruiting and lists Paroxysmal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• MY008211A Tablet (MY008211A)

Snippet

Sponsor: Wuhan Createrna Science and Technology Co., Ltd | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Status: NOT_YET_RECRUITING